Stoke Therapeutics Dravet Syndrome Drug Nears Final Development Stage

This Seeking Alpha article by analyst Sean Daly reports that Stoke Therapeutics (STOK) stock has risen 148% since his previous coverage in June 2025. The author reiterates his bullish thesis, focusing on the company's lead asset for Dravet syndrome entering its final development stretch. Daly, a finance professor and former visiting lecturer at Princeton, discloses a long position in STOK. The article provides an update on the biotech firm's progress and investment outlook, emphasizing the potential of its Dravet syndrome treatment as a key catalyst.

First published Aug 4, 02:56 PM UTCUpdated Jul 19, 06:15 AM UTC1 reports · 1 sources

Editorial responsibility

Prepared by: WorldAttention Editorial Systems
Human review: No named human review is recorded for this page.
Automated steps: Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
Page status: Current automated evidence projection
Last updated: Jul 19, 06:15 AM UTCEditorial record as of Aug 4, 02:56 PM UTC

How automation and AI are used · Report a correction or rights issue

Wire timeline

currentJul 19, 06:15 AM UTC

Stoke Therapeutics Dravet Syndrome Drug Nears Final Development Stage

Coverage sources

External reporting used to assemble this Story.

Stoke Therapeutics Dravet Syndrome Drug Nears Final Development StageAll Articles on Seeking AlphaWesternJul 19, 06:15 AM UTC

Follow the context

Princeton University Columbia University